Clinical trial
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized…
NCT00488059 · Hoffmann-La Roche, Industry · Terminated
Key facts
| NCT number | NCT00488059 |
|---|---|
| Title | A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients |
| Official title | A Multicenter, Open-label Study Evaluating the Antiviral Activity and Safety of Enfuvirtide (ENF) Once Daily (QD) or Twice Daily (BID) in Triple-class Experienced HIV-1 Infected Patients Changing Their Therapy to a Standard of Care (SOC) Regimen That Includes Initiating Raltegravir Plus an Optimized… |
| Acronym | AMICI |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Trimeris Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | enfuvirtide [Fuzeon], Optimized background ARV, Integrase inhibitor |
| Enrollment | 29 |
| Start date | Jun 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jun 19, 2007 |
| Last update posted | Jul 22, 2011 |
| Countries | Puerto Rico, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: